ReviewCancers2020
Assessment and Management of Platinum-Related Ototoxicity in Children Treated for Cancer.
Review in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 62 citations in OpenAlex.
- Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer.Cancer chemotherapy and pharmacology · 2023Trial
- Recent Advances in Anticancer Activity of Gold(I) Complexes.Biomedicines · 2026Review
- Comedication that increase the risk of cisplatin-induced hearing loss in pediatric cancer patients: a narrative literature review and meta-analysis.Frontiers in oncology · 2026Review
- The influence of tumor location on the onset of endocrine deficits in pediatric brain tumor survivors.Translational cancer research · 2025Article
- Investigating Hearing Function in Paediatric Patients with Cancer in South Africa.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2025Article
- Platinum-induced ototoxicity and hearing impairment in children and adolescents.Drugs in context · 2025Review
- Editorial: Adverse and toxic effects of childhood cancer treatments, volume II.Frontiers in oncology · 2025Article
- Drug-associated hearing impairment in children: a disproportionality analysis of the FDA adverse event reporting system.Frontiers in pharmacology · 2025Article
- The Role of the Cerebellum in Advanced Cognitive Processes in Children.Biomedicines · 2024Review
- Anthropometric parameters as a tool for the prediction of metabolic and cardiovascular risk in childhood brain tumor survivors.Diabetology & metabolic syndrome · 2024Article
- Neonatal outcomes and follow-up of children born to women with pregnancy-associated cancer: a prospective observational study.BMC pregnancy and childbirth · 2024Observational
- Hearing loss during chemotherapy: prevalence, mechanisms, and protection.American journal of cancer research · 2024Review
- Aminoglycosides-Related Ototoxicity: Mechanisms, Risk Factors, and Prevention in Pediatric Patients.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Article
- Cancer survivors and neurotoxic chemotherapy: hearing loss and tinnitus.BMJ supportive & palliative care · 2023Article
- Predicting Hearing Loss in Testicular Cancer Patients after Cisplatin-Based Chemotherapy.Cancers · 2023Article
- Cisplatin in Liver Cancer Therapy.International journal of molecular sciences · 2023Review
- Clinical and genome-wide association analysis of chemoradiation-induced hearing loss in nasopharyngeal carcinoma.Human genetics · 2023Article
- Early and Long-Term Ototoxicity Noted in Children Due to Platinum Compounds: Prevalence and Risk Factors.Biomedicines · 2023Article
- Cisplatin Induces Apoptosis in Mouse Neonatal Testes Organ Culture.International journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platinum compounds are a group of chemotherapeutic agents included in many pediatric and adult oncologic treatment protocols. The main platinum compounds are cisplatin, carboplatin, and oxaliplatin. Their use in clinical practice has greatly improved long-term survival of pediatric patients, but they also cause some toxic effects: ototoxicity, myelosuppression, nephrotoxicity, and neurotoxicity. Hearing damage is one of the main toxic effects of platinum compounds, and it derives from the degeneration of hair cells of the ear, which, not having self-renewal capacity, cannot reconstitute themselves. Hearing loss from platinum exposure is typically bilateral, sensorineural, and permanent, and it is caused by the same mechanisms with which platinum acts on neoplastic cells. According to available data from the literature, the optimal timing for the audiological test during and after treatment with platinum compounds is not well defined. Moreover, no substances capable of preventing the onset of hearing loss have been identified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.